(Q53593952)

English

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

congestive heart failure

1 reference

based on heuristic

inferred from title

1

object named as

Califf RM

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

9

object named as

Zannad F

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

14

object named as

Swedberg K

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

author name string

Adams KF

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

McKenna WJ

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Gheorghiade M

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Uretsky BF

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

McNulty SE

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Darius H

7

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Schulman K

8

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Handberg-Thurmond E

10

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Harrell FE Jr

11

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Wheeler W

12

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Soler-Soler J

13

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

language of work or name

0 references

publication date

1 July 1997

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

134

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

44-54

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Hemodynamic responses to prostacyclin (PGI2) in the conscious sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Studies on the protective effect of prostacyclin in acute myocardial ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Prostaglandins and cyclic nucleotides. Modulators of arterial cholesterol metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Heart failure in outpatients: a randomized trial of digoxin versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Development and testing of a new measure of health status for clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Group sequential clinical trials with triangular continuation regions.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Effects of beta-blockers and calcium channel blockers in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Effect of a prostacyclin derivative (iloprost) on regional blood flow, sympathetic nerve activity, and baroreceptor reflex in the conscious rat

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Hemodynamic, Hormonal, and Renal Effects of the Prostacyclin Analogue Iloprost in Conscious Dogs With and Without Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Acute hemodynamic (systemic and renal) and humoral effects of three increasing doses of iloprost in essential hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Effects of a prostacyclin analog iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoids and catecholamines in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Prostacyclin therapy in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970105-4

7 January 2021

Identifiers

10.1016/S0002-8703(97)70105-4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/9266782

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53593952&oldid=1517775272"